Many companies reported their third quarter financial results this week. Here are several that aren’t going to get a standalone write-up, as well as links to other companies, including 10x Genomics, Natera, and Pacific Biosciences.
Grail reported third-quarter total revenue of $37.5 million, up from $36.2 million a year ago, missing the consensus Wall Street estimate of $43.5 million.
Growth in its Galleri cancer screening business more than offset the near-disappearance of its development services revenue while sales and marketing spending shot up by approximately $16 million compared to Q3 2025.
Screening revenue, which reflects sales of the Galleri multi-cancer early detection test, rose 14 percent to $37.3 million from $32.8 million. Development services revenue fell to approximately $300,000. Grail processed more than 56,000 Galleri tests in the third quarter, up about 24 percent year over year.
Grail’s net loss was $103.6 million, or $2.21 per share, compared with a net loss of $89.0 million, or $2.46 per share, in the third quarter of 2025, reflecting an increased share count.
R&D expenses were $44.1 million, down from $48.6 million a year ago. SG&A expenses rose 31 percent to $82.4 million from $62.9 million, driven primarily by a 64 percent jump in sales and marketing spending to $41.7 million as the company expanded commercial efforts.
Grail ended the quarter with $788.7 million in cash, cash equivalents, and short-term marketable securities.
Qiagen reported third-quarter net sales of $547.9 million, up 3 percent from $532.6 million a year earlier, as strength in its core product lines more than offset continued softness in older parts of its portfolio.
In October, the company agreed to be taken private by Swedish private equity firm EQT.
Consumables and related revenues, which accounted for 91 percent of total sales, rose 3 percent at constant exchange rates. Instrument sales grew 1 percent at constant exchange rates.
Net income was $105.7 million for the quarter, or $0.51 per share, compared with $130.0 million, or $0.60 in the prior-year period. Adjusted EPS was $0.65.
Research and development expenses were $53.9 million, up from $48.7 million a year ago. SG&A expenses were essentially flat at $146.1 million.
BillionToOne reported third-quarter revenue of $123.0 million, up 47 percent from $83.5 million a year ago, driven by growth across its prenatal and oncology testing businesses and an 18 percent increase in average selling price.
Prenatal clinical testing revenue rose 41 percent year over year to $104.3 million. Oncology clinical testing revenue jumped 95 percent to $17.1 million. The company delivered 206,000 tests in the quarter, up 25 percent, with an overall average selling price of $589 versus $501 a year earlier.
BillionToOne reported net income of $17.4 million, or $0.32 per share, compared with net income of $5.7 million, or $0.10 per share, in Q3 2025.
R&D expenses were $20.2 million, up from $13.0 million a year earlier. BillionToOne ended the quarter with $561.5 million in cash and cash equivalents.
The company raised its full-year 2026 revenue outlook to $460.0 million to $470.0 million, representing 51 to 54 percent growth, up from its prior range of $450.0 million to $465.0 million.
BillionToOne also announced that its blood-based minimal residual disease test Northstar Clear will be commercially available Dec. 15.
Sophia Genetics reported third-quarter revenue of $24.3 million, up 25 percent from $19.5 million a year ago.
The company processed a record 118,000 analyses on its Sophia DDM platform during the quarter, up 19 percent year over year. Liquid biopsy analyses more than doubled to 4,200. Sophia ended the quarter with 551 core genomics customers, up from 488 a year earlier, and signed 30 new customers in the period. New US customers included PathGroup and the University of Arkansas for Medical Sciences.
The company’s net loss for the quarter was $20.3 million, or $0.24 per share, compared with a net loss of $20.0 million, or $0.30 per share, in the third quarter of 2025.
R&D expenses were flat at $8.3 million. SG&A expenses rose 13 percent to $25.5 million from $22.6 million.
Revenue growth was strongest in North America, up 45 percent, and in Asia Pacific, up 33 percent.
Sophia ended the quarter with $93.7 million in cash and equivalents.
Previous coverage
Natera Appoints New CEO, Makes Mystery $30M Acquisition
Natera announced that it has appointed Solomon Moshkevich as CEO, effective immediately. Separately, the company disclosed it made a $30 million acquisition on Nov. 2.
10x Genomics Preps for Atera Era Even as Spatial Instrument Revenue Dips
This story has been updated to include additional details about 10x Genomics’ legal proceedings with Illumina and Spatial Genomics.
PacBio Reusable Consumables Sales Grow, Enabling Project Wins in Q3
Customers are buying Pacific Biosciences new reusable sequencing chips, the company reported Nov. 4 along with its third-quarter financial results.
Guardant's Shield Test Hits 83K Tests in Q3, Driving 36 Percent Jump in Revenue
Guardant Health’s Shield colorectal cancer screening test volume more than tripled year over year in the third quarter, reaching 83,000 tests compared to 24,000 a year ago.